Michael Glover, Isabel Beshar, Austin McHenry, Cornelia Ding, Oliver Dorigo, Emily Chan, Sumit A Shah
{"title":"Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.","authors":"Michael Glover, Isabel Beshar, Austin McHenry, Cornelia Ding, Oliver Dorigo, Emily Chan, Sumit A Shah","doi":"10.1159/000545141","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics.</p><p><strong>Case presentation: </strong>In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical, radiological, and molecular response to combination treatment of antibody-drug conjugate enfortumab vedotin (EV) with pembrolizumab.</p><p><strong>Conclusion: </strong>This is the first reported response to this combination therapy in vaginal cancer in the literature. The patient had positive Nectin-4 staining on evaluation, raising the possibility for future clinical application of EV in vaginal squamous cell cancer.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"473-479"},"PeriodicalIF":0.7000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999660/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000545141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Vaginal cancer is a rare yet aggressive cancer, with unmet need for novel therapeutics.
Case presentation: In this case report, we present a patient with advanced stage, HPV-positive vaginal cancer who demonstrated clinical, radiological, and molecular response to combination treatment of antibody-drug conjugate enfortumab vedotin (EV) with pembrolizumab.
Conclusion: This is the first reported response to this combination therapy in vaginal cancer in the literature. The patient had positive Nectin-4 staining on evaluation, raising the possibility for future clinical application of EV in vaginal squamous cell cancer.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
